The Food and Drug Administration Friday alerted clinical laboratory staff and health care providers to the potential for false positive results with two test kits made by Abbott Molecular to detect SARS-CoV-2. The agency recommends providers consider presumptive any positive results from the Alinity m SARS-CoV-2 AMP Kit, List Number 09N78-095, and Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096; consider retesting positive patient specimens performed in the last two weeks with an alternate authorized test and informing patients with positive results since June that their results may have been false positives; and report any issues using the tests to FDA. Only laboratories certified to perform moderate or high complexity tests under the Clinical Laboratory Improvement Amendments can use these test kits.

Related News Articles

Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
Texas this week filed a federal lawsuit challenging the Centers for Medicare & Medicaid Services’ interim final rule requiring COVID-19 vaccinations…
Headline
Nursing home visitation is now allowed for all residents at all times, according to updated guidance released Friday by the Centers for Medicare &…
Headline
To ensure that COVID-19 tests work as intended, the Food and Drug Administration will now enforce premarket review requirements for laboratory developed tests…
Headline
The Centers for Disease Control and Prevention will implement three new ICD-10 diagnosis codes for reporting COVID-19 vaccination status effective April 1,…
Headline
Ellume has expanded its recall of rapid at-home COVID-19 antigen tests to about 2 million tests, the Food and Drug Administration said in an update this week.…